

# AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms

NCT05198960

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 3
<b>Sponsor</b>	University Hospital, Brest
<b>Enrollment</b>	1,308 participants

## Key Eligibility Criteria

---

### Inclusion (6)

- Patients with diagnosis of PV or ET or PreMF according to WHO or BSCH criteria (bone marrow biopsy not compulsory).
- Patients with JAK2V617F mutation (threshold allele burden  $\geq 1\%$ ).
- Patients considered as "high-risk" patients:
  - based on age ( $\geq 60$ -year-old)
  - based on thrombotic history (compatible with antithrombotic randomization) but aged  $\geq 18$ -year-old.
- ... and 1 more (see full listing online)

### Exclusion (11)

- Contra-indication to aspirin or DOAC due to allergic situation or recent history of major bleeding.
- Formal indication of treatment with aspirin or DOAC (thus precluding randomization).
- Inability to give informed consent.
- Patients under curatorship/guardianship
- Concomitant use of a strong inhibitor or inducer of CYP3A4 (like ruxolitinib).
- ... and 6 more (see full listing online)

## Locations (42 total)

---

CHU d'Angers, Angers, France  
CH d'Annecy, Annecy, France  
CH d'Argenteuil, Argenteuil, France  
... and 39 more locations

---

<https://clinicaltrials.gov/study/NCT05198960>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).